Jan 12 2010
Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals announced today the launch of Ibutilide Fumarate Injection, the generic equivalent of Corvert
® from Pfizer Inc.
"The addition of Ibutilide Fumarate Injection further demonstrates Bioniche Pharma's continued growth and dedication to a consistently expanding portfolio of injectables," said George Zorich, President, US Operations for Bioniche Pharma.
Bioniche Pharma will supply Ibutilide Fumarate Injection in 0.1 mg/mL, 10mL vials.
This product has a boxed warning relating to proarrhythmic effects including potentially fatal arrhythmias (e.g., polymorphic ventricular tachycardia) and consideration for use in patients with chronic atrial fibrillation. Please refer to the Bioniche Pharma website at www.bionichepharma.com for the complete prescribing information for this product, including the boxed warning.
SOURCE Bioniche Pharma
MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals